The Hot Emerging Area Of Cancer Vaccines And Tumour Immunity
Posted on: Friday, 15 February 2008, 06:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c82987) has announced the addition of "Cancer Vaccines and Tumour Immunity" to their offering.
Cancer vaccine development has changed from a small-scale academic enterprise in to an applied science requiring a large clinical research infrastructure. In this book, a team of expert contributors take a focused look at the hot emerging area of cancer vaccines and tumour immunity. Cancer Vaccines and Tumour Immunity serves a unique role in that it presents as a continuum the basic science discoveries that have moved forward into clinical trials. It is a one-stop, concise reference for all those interested in cancer vaccines, summarizing where we have come from, demonstrating what we are currently doing, and identifying the next major advances.
Discusses how our new and developing understanding of T-regulatory cells and autoimmunity will impact cancer vaccine design
Offers a unique look forward into how vaccination in the context of bone marrow transplantation will open new avenues for clinical study
Offers an exceptional presentation of how modern genomic analysis of normal and tumour tissue will help to identify the next generation of cancer vaccine targets
Author Info:
Rimas J. Orentas, PhD, is Associate Professor in the Department of Pediatrics, Section of Hematology-Oncology, and holds joint appointments in the Departments of Medicine and Microbiology and Molecular Genetics at the Medical College of Wisconsin in Milwaukee, Wisconsin.
JAMES W. HODGE, PhD, is a Senior Scientist in the Laboratory of Tumour Immunology and Biology at the National Cancer Institute in Bethesda, Maryland.
BRYON D. JOHNSON, PhD, is Associate Professor in the Department ofPediatrics, Section of Hematology-Oncology at the Medical College of Wisconsin in Milwaukee, Wisconsin.
Contents:
FORWARD. Cancer Vaccines and Cancer Immunotherapy. A New Paradigm. Jeffrey Schlom.
OVERVIEW.
Chapter 1. Cancer Vaccines. Progress and Promise. Rimas J. Orentas, Bryon Johnson, and James Hodge.
PART I. ADJUVANT THERAPY: ENHANCING THE ENDOGENOUS IMMUNE RESPONSE.
Chapter 2. Fully Synthetic Carbohydrate-Based Anti-Tumour Vaccines. Rebecca M. Wilson and Samuel J. Danishefsky.
Chapter 3. Bacillus Calmette-Guerin Immunotherapy of Genitourinary Cancer. Donald L. Lamm.
Chapter 4. Stimulation of Toll-like Receptor 9 for Enhancing Vaccination. Daniel E. Speiser and Arthur M. Krieg.
PART II. ANTIGEN-SPECIFIC THERAPY: NOVEL PRESENTATION OF PEPTIDE AND PROTEIN ANTIGENS.
Chapter 5. Polyepitope Vaccines. Corey Smith and Rajiv Khanna.
Chapter 6. Antigen-Specific Cancer Immunotherapy: HPV-Associated Cervical Cancer as a Model System. Shaw-Wei D. Tsen, Chien-Fu Hung, and T.-C. Wu.
Chapter 7. Poxviral vectors for cancer vaccines: state of the art. Elizabeth K. Wansley.
Chapter 8. Immunotherapeutic strategies against cancer using Listeria monocytogenes as a vector for tumour antigens. Nicholas C. Souders, Thorsten Verch and Yvonne Paterson.
Chapter 9. Coupling Innate and Adaptive Immunity with Yeast-based Cancer Immunotherapy. Sibyl Munson, Joanne Parker, Tom King, Yingnian Lu, Victoria Kelley, Zhimin Guo, Virginia Borges, and Alex Franzusoff.
PART III. CELL-BASED THERAPY: USING CANCER CELLS AS A MEANS TO INDUCE SPECIFIC TUMOR IMMUNITY.
Chapter 10. Allogeneic Whole Cell Vaccines. John Copier and Angus Dalgleish.
Chapter 11. Jump-Starting Tumour Immunity with Breast Cancer Therapeutics. Leisha A. Emens.
Chapter 12. T Regulatory Cell Manipulation in Tumour Immunotherapy. Jens Rüter, Brian G. Barnett, Ilona Kryczek, Michael J. Brumlik, Benjamin J. Daniel, George Coukos, Weiping Zou, Tyler J. Curiel.
Chapter 13. Tumour Vaccination after Autologous HSCT: What has been Learned from Experimental Models? Weiqing Jing and Bryon D. Johnson.
Chapter 14. Vaccines in the Setting of Hematopoietic Stem Cell Transplantation. Ronald Gress and Claude Sportes.
Chapter 15. Intra-tumour generation of vigorous anti-tumour immune responses. Ping Yu and Yang-Xin Fu.
Chapter 16. Cancer Immunotherapy: Untapping the Potential of Co-Stimulatory Molecules Beyond CTLA-4. Mathew Augustine, and Lieping Chen.
PART IV. DEFINING EFFECTIVE CLINICAL RESPONSES.
Chapter 17. Immune Evaluation of Cancer Vaccines. Theresa L. Whiteside.
Chapter 18. Advances in Immune Monitoring Strategies for Cancer Vaccines and Immunotherapy. Seunghee Kim-Schulze, Moshe Ornstein and Howard L. Kaufman.
For more information visit http://www.researchandmarkets.com/reports/c82987
Source: Business Wire
Related Articles
- GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
- eDispense(TM) Vaccine Manager to Process Physician Administration Fees for Vaccines Covered Under Medicare Part D
- Research and Markets : Cancer Drug Discoveries: What the Future Holds: Breast Cancer Chapter
- Vical DNA Vaccine Elicits Lasting Memory T-Cell Immune Responses in Humans
- Novavax's Pandemic Influenza Vaccine Candidates Trigger Robust Immune Response In Pre-Clinical Models
- Broad T-Cell Immunity Against HIV Generated in Prime-Boost Vaccine Phase 1 Trial
- Progenics Pharmaceuticals Initiates Clinical Trial of Viral-Entry Inhibitor PRO 140 in HIV-Infected Patients; Monoclonal Antibody Designed to Block HIV Infection of Immune System Cells
- 'Underground' tunnels discovered as means for communication between immune system cells
- 'License to Kill' Enables Powerful Immune Attack Cells in Mice
- Breast Cancer Uses Growth Factors to Lure Stem Cells
 |
 |
User Comments (0)
RSS Feeds